Analysis of the success rates of new drug development in Japan and the lag behind the US

Yuka Hirai, Yosuke Yamanaka, Makiko Kusama, Taro Ishibashi, Yuichi Sugiyama and Shunsuke Ono

Health Policy, 2012, vol. 104, issue 3, 241-246

Abstract: The launch delay of new drugs has been a major public concern in Japan. Although it is recognized that the delay results from industrial R&D behaviors and regulatory conditions in the global market, the specific mechanisms underlying the significant delay have been unexplained. This study analyzed the association between the success rates of clinical development programs of new molecular entities in Japan and the development lag behind the US and provides clues for policy planning.

Keywords: Pharmaceuticals; Research and development; Policy; Japan; Drug industry; Risk management (search for similar items in EconPapers)
Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S016885101100248X
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:104:y:2012:i:3:p:241-246

DOI: 10.1016/j.healthpol.2011.11.008

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().